5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve ...
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ...
Dublin, Sept. 14, 2021 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cell (iPSC) Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ...
DUBLIN, April 15, 2021 /PRNewswire/ -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021" report has been added to ResearchAndMarkets.com's offering. The main objectives of ...
Hamburg, Germany, 02 September 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that Bristol Myers Squibb Company (NYSE:BMY) has exercised its option to ...
- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - - Company announces plans for Phase 1 ELiPSE-1 trial of CNTY-101 ...
BEIJING and SHANGHAI and BOSTON, Aug. 31, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals ("Jacobio", 1167.HK) announced a strategic investment in the US-based biotech company Hebecell on August 31.
iPSC technology allows for the development of next-generation cell therapy products as a key addition to Bone Therapeutic’s existing cell therapy platform Gosselies, Belgium and Beltsville, MA, US, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback